Chemically Programmable and Switchable CAR-T Therapy

被引:35
|
作者
Qi, Junpeng [1 ]
Tsuji, Kohei [2 ,3 ]
Hymel, David [2 ]
Burke, Terrence R., Jr. [2 ]
Hudecek, Michael [4 ]
Rader, Christoph [1 ]
Peng, Haiyong [1 ]
机构
[1] Scripps Res Inst, Dept Immunol & Microbiol, 130 Scripps Way, Jupiter, FL 33458 USA
[2] NCI, Biol Chem Lab, Ctr Canc Res, NIH, Bldg 376 Boyles St, Frederick, MD 21702 USA
[3] Tokyo Med & Dent Univ, Inst Biomat & Bioengn, Dept Med Chem, Chiyoda Ku, 2-3-10 Kandasurugadai, Tokyo 1010062, Japan
[4] Univ Klinikum Wurzburg, Med Klin & Poliklin 2, Oberdurrbacherstr 6, D-97080 Wurzburg, Germany
基金
美国国家卫生研究院;
关键词
antibodies; antitumor agents; cell-surface receptors; CAR-Ts; immunotherapy; BISPECIFIC ANTIBODIES; ALDOLASE ANTIBODY; FOLATE RECEPTOR; CELLS; IMMUNOTHERAPY; MOLECULES; SELECTION; STRATEGY;
D O I
10.1002/anie.202005432
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Although macromolecules on cell surfaces are predominantly targeted and drugged with antibodies, they harbor pockets that are only accessible to small molecules and constitutes a rich subset of binding sites with immense potential diagnostic and therapeutic utility. Compared to antibodies, however, small molecules are disadvantaged by a less confined biodistribution, shorter circulatory half-life, and inability to communicate with the immune system. Presented herein is a method that endows small molecules with the ability to recruit and activate chimeric antigen receptor T cells (CAR-Ts). It is based on a CAR-T platform that uses a chemically programmed antibody fragment (cp-Fab) as on/off switch. In proof-of-concept studies, this cp-Fab/CAR-T system targeting folate binding proteins on the cell surface mediated potent and specific eradication of folate-receptor-expressing cancer cells in vitro and in vivo.
引用
收藏
页码:12178 / 12185
页数:8
相关论文
共 50 条
  • [1] Engineering switchable and programmable universal CARs for CAR T therapy
    Delong Liu
    Juanjuan Zhao
    Yongping Song
    Journal of Hematology & Oncology, 12
  • [2] Engineering switchable and programmable universal CARs for CAR T therapy
    Liu, Delong
    Zhao, Juanjuan
    Song, Yongping
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2019, 12 (1)
  • [3] AbbVie invests in Calibr's switchable CAR-T therapy
    Cross, Ryan
    CHEMICAL & ENGINEERING NEWS, 2018, 96 (27) : 10 - 10
  • [4] ROR1-targeting switchable CAR-T cells for cancer therapy
    Haiyong Peng
    Thomas Nerreter
    Katrin Mestermann
    Jakob Wachter
    Jing Chang
    Michael Hudecek
    Christoph Rader
    Oncogene, 2022, 41 : 4104 - 4114
  • [5] ROR1-targeting switchable CAR-T cells for cancer therapy
    Peng, Haiyong
    Nerreter, Thomas
    Mestermann, Katrin
    Wachter, Jakob
    Chang, Jing
    Hudecek, Michael
    Rader, Christoph
    ONCOGENE, 2022, 41 (34) : 4104 - 4114
  • [6] A novel switchable car-T cell therapy for tumor retargeting and improved safety
    Castellarin, M.
    Sands, C.
    Young, R.
    June, C.
    CYTOTHERAPY, 2020, 22 (05) : S18 - S19
  • [7] ROR1-targeting switchable CAR-T cells for cancer therapy
    Peng, Haiyong
    Nerreter, Thomas
    Mestermann, Katrin
    Wachter, Jakob
    Chang, Jing
    Hudecek, Michael
    Rader, Christoph
    ONCOGENE, 2022,
  • [8] Genetically Programmable Vesicles for Enhancing CAR-T Therapy against Solid Tumors
    Li, Xianjun
    Zhu, Tianchuan
    Wang, Ronghao
    Chen, Jian
    Tang, Lantian
    Huo, Wenwen
    Huang, Xi
    Cao, Qingdong
    ADVANCED MATERIALS, 2023, 35 (19)
  • [9] CAR-T Cell Therapy
    Ahmad, Aamir
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (12)
  • [10] CONTROLLING CAR-T THERAPY
    Cross, Ryan
    CHEMICAL & ENGINEERING NEWS, 2018, 96 (19) : 32 - 37